- Home
- PIM vs VTVT Comparison
PIM vs VTVT Comparison
Compare PIM & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PIM | VTVT |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 143.7M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | PIM | VTVT |
|---|---|---|
| Price | $3.21 | $35.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $55.25 |
| AVG Volume (30 Days) | ★ 60.8K | 29.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $1,017,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $64.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.14 | $14.00 |
| 52 Week High | $3.50 | $44.00 |
Technical Indicators
Market Signals| Indicator | PIM | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 33.41 | 49.53 |
| Support Level | N/A | $33.62 |
| Resistance Level | $3.37 | $42.71 |
| Average True Range (ATR) | 0.03 | 3.17 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 17.65 | 29.90 |
Price Performance
Historical ComparisonAbout PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.